Supreme Court Shouldn't Hear Tamoxifen Cases: SG

Law360, New York (May 23, 2007, 12:00 AM EDT) -- The U.S. Supreme Court should not use the Tamoxifen Citrate antitrust lawsuits as an opportunity to weigh in on the issue of authorized generics, even though the appeals court that decided the case mistakenly relied on an overly stringent standard, the Solicitor General’s Office said Wednesday.

“The United States submits that the petition for a writ of certiorari should be denied,” the SG said in a brief on Wednesday. “Although the petition presents an important and difficult question, and the court of appeals adopted an incorrect...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.